How CS Venkatakrishnan Led Barclays Through Cancer Treatment and a Major Turnaround

Barclays chief executive C.S. Venkatakrishnan has overseen a dramatic rise in the bank’s market value while navigating one of the most difficult periods of his personal life — treatment for cancer.

Known widely as Venkat, the Indian-born banking executive took over as Group Chief Executive of Barclays in November 2021. Less than a year later, he revealed that he had been diagnosed with non-Hodgkin lymphoma.

Despite undergoing treatment, Venkatakrishnan remained actively involved in running one of Britain’s biggest banks, while adjusting his schedule and working remotely when necessary.

Today, Barclays is worth substantially more than when he took charge, with recent estimates suggesting the bank has generated roughly £40 billion in additional shareholder value during his tenure.

Cancer Diagnosis Came Just a Year Into the Top Job

Venkatakrishnan’s cancer diagnosis was publicly announced in November 2022.

At the time, he told employees that doctors had detected the non-Hodgkin lymphoma early and described it as highly localised. His treatment was expected to last between 12 and 16 weeks in New York.

Rather than stepping away completely, he said he intended to remain actively involved in managing Barclays, although treatment meant periods of working from home and restrictions on travel.

The bank did not appoint an interim chief executive, with Venkatakrishnan and Barclays’ executive committee continuing to oversee operations.

Treatment Completed and Cancer in Remission

In March 2023, Venkatakrishnan announced that he had completed treatment.

He said he was in remission, with no evidence of disease, and planned to gradually return to working more frequently from the office and resume travelling.

He also used the announcement to encourage employees to pay attention to their physical and mental wellbeing and make use of the health support available to them.

His ability to continue leading during treatment became an unusually public example of a major corporate chief executive balancing serious illness with the responsibilities of running a global financial institution.

Barclays’ Value Has Risen Sharply

The financial transformation of Barclays during Venkatakrishnan’s tenure has also attracted attention.

When he became chief executive in late 2021, Barclays’ market capitalisation was around the £30 billion to £40 billion range, depending on the exact measurement date.

By August 2026, its London-listed market value had climbed to approximately £68 billion, while it had reached even higher levels earlier in the year.

Business Leader, following an interview with Venkatakrishnan published in July 2026, estimated that he had helped add roughly £40 billion in shareholder value during his period at the helm.

The figure should be viewed as an approximate measure of the rise in Barclays’ equity value rather than value attributable to one individual alone, as share prices are influenced by interest rates, market conditions, economic growth and investor sentiment as well as management decisions.

A Major Strategic Reset

A significant part of Venkatakrishnan’s leadership has centred on reshaping Barclays to generate stronger and more predictable returns.

The bank has sought to balance its large investment-banking operation with greater emphasis on businesses including:

•    UK retail banking
•    Corporate banking
•    Wealth management
•    Consumer finance
•    Payments
•    Investment banking and global markets

The strategy has also focused heavily on improving efficiency, controlling costs and returning more capital to shareholders.

Barclays’ 2025 results showed that the bank delivered all of its financial guidance for the year, recording a return on tangible equity of 11.3%.

It distributed £3.7 billion to shareholders during 2025, including share buybacks, and subsequently announced an ambition to return more than £15 billion of capital between 2026 and 2028.

Strong Momentum Continues in 2026

Barclays continued to report improving financial performance during the first half of 2026.

For the six months ending June 30, the banking group reported:

Group income: £16.5 billion
Profit before tax: £6.1 billion
Return on tangible equity: 14.8%
Earnings per share: 30.7p
Capital distributions announced: £2.3 billion
During the second quarter alone, profit before tax reached £3.3 billion, up 31% year-on-year, while quarterly return on tangible equity climbed to 16.1%.
The strong performance prompted Barclays to increase its 2026 group income target to approximately £31.5 billion.

From Risk Management to Barclays CEO

Venkatakrishnan brought decades of banking experience to the top position.

Before becoming chief executive, he served as Barclays’ Chief Risk Officer and later as Head of Global Markets and Co-President of Barclays Bank PLC.

Before joining Barclays in 2016, he spent more than two decades at JPMorgan, working across asset management, investment banking and risk.

His background in risk management became particularly relevant as Barclays navigated volatile interest rates, regulatory changes and uncertainty across global financial markets.

Leadership Under Extraordinary Pressure

Corporate turnarounds are normally measured through earnings, returns and share prices.

Venkatakrishnan’s tenure has included another dimension: leading a global bank while undergoing treatment for a potentially life-threatening illness.

He did not present his experience as a story of working through illness at any cost. Instead, his public comments repeatedly highlighted healthcare, wellbeing and the importance of using professional support.

That distinction matters.

His story is not simply about remaining at work during cancer treatment. It is about maintaining leadership continuity while receiving medical care, delegating responsibilities when necessary and later returning to a more normal working routine following remission.

Barclays Still Faces Challenges

Despite the strong improvement in Barclays’ valuation and profitability, the transformation is not complete.

The bank continues to face intense competition from major American investment banks, pressure to improve returns, regulatory changes and the challenge of balancing growth with disciplined use of capital.

Barclays has also continued adjusting the leadership and structure of its investment bank as it seeks to improve efficiency and strengthen its competitive position.
Venkatakrishnan’s ability to meet the bank’s longer-term targets will therefore ultimately determine how investors judge his tenure.

A Remarkable Corporate Leadership Story

From a cancer diagnosis less than a year after taking the top job to overseeing one of Barclays’ strongest periods of market-value growth in years, C.S. Venkatakrishnan’s tenure has been anything but conventional.

Barclays’ improvement cannot be attributed to a single person, and external economic conditions have played an important role.

Yet the combination of a major strategic overhaul, improving profitability, billions of pounds returned to shareholders and Venkatakrishnan’s personal battle with cancer has created one of the more remarkable leadership stories in modern British banking.